HER2-low heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer

被引：0
|
作者：
Zou, Y. [1 ]
Deng, X. [1 ]
Xie, J. [1 ]
Zeng, Y. [2 ]
Jing, B. [1 ]
Fu, J. [1 ]
Jiang, Y. [1 ]
Tang, H. [1 ]
Liu, P. [1 ]
Xie, X. [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Dept Breast Oncol, Guangzhou, Peoples R China
[2] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.059
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
37MO
引用
收藏
页码：S1418 / S1418
页数：1
相关论文
共 50 条
  • [1] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Carroll, Hailey K.
    Higgins, Michaela J.
    O'Reilly, Seamus
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1144 - 1144
  • [2] Trastuzumab and Deruxtecan Combination for Survival Benefit in Patients with HER2-low Breast Cancer
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (10)
  • [3] TRASTUZUMAB DERUXTECAN IS EFFECTIVE IN HER2-LOW BREAST CANCER
    不详
    CANCER DISCOVERY, 2020, 10 (04) : 488 - 488
  • [4] Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+and HER2-low Breast Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    Fatima, Eeshal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 535 - 541
  • [5] Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Tarantino, P.
    Tolaney, S. M.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 949 - 950
  • [6] Fam-Trastuzumab Deruxtecan-nxki in metastatic HER2-low breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 779 - 779
  • [7] Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
    Poumeaud, F.
    Morisseau, M.
    Cabel, L.
    Goncalves, A.
    Rivier, C.
    Tredan, O.
    Volant, E.
    Frenel, J. -s.
    Ladoire, S.
    Jacot, W.
    Jamelot, M.
    Foka Tichoue, H.
    Patsouris, A.
    Teixeira, L.
    Bidard, F. -c.
    Loirat, D.
    Brunet, M.
    Levy, C.
    Bailleux, C.
    Cabarrou, B.
    Deleuze, A.
    Uwer, L.
    Deluche, E.
    Grellety, T.
    Franchet, C.
    Fiteni, F.
    Bischoff, H.
    Vion, R.
    Pagliuca, M.
    Verret, B.
    Becourt, S.
    Reverdy, T.
    de Nonneville, A.
    Dalenc, F.
    BRITISH JOURNAL OF CANCER, 2024, 131 (04) : 702 - 708
  • [8] PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Hennig, S.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S93 - S94
  • [9] The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Wei, T.
    Wang, D.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 948 - 949
  • [10] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joohyuk
    Vidal, Maria
    Tokunaga, Eriko
    Tsurutani, Junji
    Ueno, Naoto T.
    Prat, Aleix
    Chae, Yee Soo
    Lee, Keun Seok
    Niikura, Naoki
    Park, Yeon Hee
    Xu, Binghe
    Wang, Xiaojia
    Gil-Gil, Miguel
    Li, Wei
    Pierga, Jean-Yves
    Im, Seock-Ah
    Moore, Halle C. F.
    Rugo, Hope S.
    Yerushalmi, Rinat
    Zagouri, Flora
    Gombos, Andrea
    Kim, Sung-Bae
    Liu, Qiang
    Luo, Ting
    Saura, Cristina
    Schmid, Peter
    Sun, Tao
    Gambhire, Dhiraj
    Yung, Lotus
    Wang, Yibin
    Singh, Jasmeet
    Vitazka, Patrik
    Meinhardt, Gerold
    Harbeck, Nadia
    Cameron, David A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (01): : 9 - 20
12345